Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept

Detalles Bibliográficos
Autores principales: Guermazi, Dorra, Arvanitis, Panos, Farmakiotis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066965/
https://www.ncbi.nlm.nih.gov/pubmed/37004695
http://dx.doi.org/10.1007/s15010-023-02027-6
_version_ 1785018363248902144
author Guermazi, Dorra
Arvanitis, Panos
Farmakiotis, Dimitrios
author_facet Guermazi, Dorra
Arvanitis, Panos
Farmakiotis, Dimitrios
author_sort Guermazi, Dorra
collection PubMed
description
format Online
Article
Text
id pubmed-10066965
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-100669652023-04-03 Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept Guermazi, Dorra Arvanitis, Panos Farmakiotis, Dimitrios Infection Correspondence Springer Berlin Heidelberg 2023-04-01 /pmc/articles/PMC10066965/ /pubmed/37004695 http://dx.doi.org/10.1007/s15010-023-02027-6 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Correspondence
Guermazi, Dorra
Arvanitis, Panos
Farmakiotis, Dimitrios
Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept
title Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept
title_full Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept
title_fullStr Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept
title_full_unstemmed Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept
title_short Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept
title_sort molnupiravir efficacy among immunocompromised patients with covid-19: no proof of concept
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066965/
https://www.ncbi.nlm.nih.gov/pubmed/37004695
http://dx.doi.org/10.1007/s15010-023-02027-6
work_keys_str_mv AT guermazidorra molnupiravirefficacyamongimmunocompromisedpatientswithcovid19noproofofconcept
AT arvanitispanos molnupiravirefficacyamongimmunocompromisedpatientswithcovid19noproofofconcept
AT farmakiotisdimitrios molnupiravirefficacyamongimmunocompromisedpatientswithcovid19noproofofconcept

Ejemplares similares